| abstract |
The present invention relates to trans-capsularly administering into a diseased joint a high specificity antagonist selected from the group consisting of: i) an inhibitor of a pro-inflammatory interleukin; ii) an inhibitor of TNF-alpha synthesis; iii) an inhibitor of membrane-bound TNF-alpha; iv) an inhibitor of a natural receptor of TNF-alpha; v) an inhibitor of NO synthase, vi) an inhibitor of PLA2 enzyme; vii) an anti-proliferative agent; viii) an anti-oxidant; ix) an apoptosis inhibitor selected from the group consisting of EPO mimetic peptides, EPO mimetibodies, IGF-1, IFG-II, and caspase inhibitors, and x) an inhibitor of MMPs; and xi) an inhibitor of p38 kinase. Conpounds include Rapamycin, NG-Monomethyl-L-Arginine, Infliximab, L-NIL, IGF-1, IGF-2. |